HOME >> BIOLOGY >> NEWS
New drug enfuvirtide shows promise against drug resistant HIV infection

CHAPEL HILL -- The new drug enfuvirtide, a member of a new class of medications designed to combat HIV -- the virus that causes AIDS -- shows strong promise in treating drug-resistant cases of the life-threatening infection, a study conducted with patients in North and South America concludes.

A report on the research appears in the May 29 issue of the New England Journal of Medicine.

"This is one of the most important studies performed to date in HIV-infected patients who have already received highly active antiretroviral therapy (HAART) and a landmark study for the field of HIV," said Dr. Joseph Eron of the University of North Carolina at Chapel Hill and a report author.

"The clinical work clearly demonstrates that a completely new class of anti-HIV medication, developed by a local company, Trimeris, is highly effective in a very large randomized study," said Eron, associate professor of medicine at the UNC School of Medicine.

"Enfuvirtide, or T-20, works by blocking HIV entry into CD4 + lymphocytes or T-cells and will benefit patients who already have HIV that is resistant to current therapy."

CD4+ lymphocytes, also known as T-cells, are a key part of the body's immune system for fighting off disease-causing viruses, bacteria and various other organisms, he said. HIV is so deadly because it kills those defenders and leaves patients vulnerable to a wide variety of debilitating illnesses.

Fuzeon is enfuvirtide's trade name.

Another report of a second study with similar results carried out in Europe and Australia also appears in the May 29 issue of the journal. Eron and Dr. J. Michael Kilby of the University of Alabama at Birmingham have a third article in the journal describing T-20 and other drugs now in development in the new class of HIV medications called entry inhibitors.

Dr. Jacob P. Lalezari of Quest Clinical Research, Mount Zion Hospital and the University of California at San Francisco led
'"/>

Contact: David Williamson
919-962-8596
University of North Carolina at Chapel Hill
28-May-2003


Page: 1 2 3

Related biology news :

1. New study shows hope for treating inhalant abuse
2. Chemical derived from vitamin-E shows early promise as cancer drug
3. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
4. Trial shows which brain cancer patients benefit from temozolomide
5. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
6. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
7. Simian virus 40 not associated with non-Hodgkin lymphoma, study shows
8. A probable cause for high blood pressure identified - shows links with diabetes
9. Blue marlin in gulf have high mercury levels, A&M study shows
10. New research shows air pollution can reduce childrens lung function
11. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows

Post Your Comments:
(Date:7/8/2015)... FRANKLIN LAKES , N.J. and NEW YORK ... and Company) and Guidepoint today announced ... selected start-up healthcare companies with free access to Guidepoint,s ... mentoring several start-ups that are developing cutting-edge technologies to ... of a dedicated Guidepoint research manager, each start-up entrepreneur ...
(Date:7/8/2015)... 2015 The consumer products industry for ... have products such as wearables, smart wallets & other smart ... based devices continues to rapidly grow.  Biometrics & Wearable Device ... ), Google Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... Inc. (NASDAQ: GPRO ) and Baidu Inc. (NASDAQ: ...
(Date:7/7/2015)... , July 7, 2015  Based on ... Frost & Sullivan recognizes Credence ID, LLC with ... Entrepreneurial Company of the Year Award. Credence ID ... aid in its mission of offering enrollment and ... globally. As Credence ID was formed by experts ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
(Date:7/30/2015)... ... ... of its 2015 growth plan and as a follow up to the recently announced expansion ... is pleased to announce that it has begun construction on a new Microbiological Laboratory. The ... strictly dedicated to basic USP 51, USP 61, and USP 62 testing specific to raw ...
(Date:7/29/2015)... 2015 US-Australian drug discovery company, Novogen Limited ... is committed to progressing its ground-breaking technology platforms to ... to ensure the Company delivers the best value for ... Ross , said the Company currently had an extensive ... discovery programs and academic partnerships and initiatives, and he ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... manufacturer and supplier, announces the launch of their 2nd generation cell therapy POD® ... current miniPOD CT, but it also represents a new POD® design. , ...
(Date:7/29/2015)... 29, 2015  Pfenex Inc. (NYSE MKT: PFNX) announced ... be released on Thursday, August 13, 2015, before the ... management will host a conference call to discuss the ... release outlining the financial results and business update will ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference ...
Breaking Biology Technology:Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2
Cached News: